Free shipping on all orders over $ 500

Icrucumab

Cat. No. M24537
Icrucumab Structure
Synonym:

Anti-VEGFR1/FLT1 Reference Antibody IMC-18F1

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors.

Chemical Information
CAS Number 1024603-92-6
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Gang Yin, et al. J Chemother. Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials

[2] Linda T Vahdat, et al. Oncologist. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

[3] M Moore, et al. Ann Oncol. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

[4] Daniel P Petrylak, et al. J Clin Oncol. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

[5] Patricia M LoRusso, et al. Invest New Drugs. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

Related VEGFR/PDGFR Products
Pegaptanib Sodium

Pegaptanib Sodium is an RNA aptamer targeting vascular endothelial growth factor (VEGF)-165, a molecule of oligonucleotides chemically linked to polyethylene glycol (PEG), which can be used in studies related to neovascular age-related macular degeneration (AMD).
Jolkinolide A

Jolkinolide A is a diterpenoid, which exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells.
N-(p-Coumaroyl) Serotonin

N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on phosphorylation of PDGF receptor and Ca2+ release from sarcoplasmic reticulum. N-(p-Coumaroyl) Serotonin ameliorates atherosclerosis and distensibility of the aortic wall in vivo and is usually used for the atherosclerosis research.
VEGFR-2-IN-5 hydrochloride 

VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor.
AMG-Tie2-1 

AMG-Tie2-1 is an inhibitor of tunica interna endothelial cell kinase 2 (Tie2) with an IC50 of 1 nM. AMG-Tie2-1 is a VEGFR2 inhibitor with an IC50 of 3 nM.
  Catalog
Abmole Inhibitor Catalog




Keywords: Icrucumab, Anti-VEGFR1/FLT1 Reference Antibody IMC-18F1 supplier, VEGFR/PDGFR, inhibitors, activators

 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.